X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XOMA acquired potential milestones and mid-single digit royalties associated with Ojemda (tovorafenib), approved for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring BRAF V600 mutation.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: Ojemda
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: XOMA
Deal Size: $54.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 25, 2024
Details:
Ojemda (tovorafenib) is a a type II RAF inhibitor small molecule drug candidate. It is approved for the treatment of relapsed or refractory braf-altered pediatric low-grade glioma (pLGG) in patients 6 months of age and older.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: Ojemda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatric low-grade glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: XOMA
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 31, 2023
Details:
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in relapsed or progressive pediatric low-grade glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Under the agreement, Day One receives an exclusive license to develop and commercialize small molecule drug candidates targeting Vaccinia-related kinase 1 (VRK1), for pediatric and adult cancers with high unmet need.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Sprint Bioscience
Deal Size: $316.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement August 16, 2023
Details:
The net proceeds will be used to fund Day One’s lead product candidate, DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor, under evaluation for the treatment of pediatric low-grade glioma (pLGG) and solid tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 12, 2023
Details:
The net proceeds will be used to fund Day One’s lead product candidate, DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor, under evaluation for the treatment of pediatric low-grade glioma (pLGG) and solid tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 06, 2023
Details:
DAY101 (tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumors.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
Under the terms of the CRADA, NCI investigators will have the opportunity to study tovorafenib (DAY101) in CTEP-sponsored trials to be conducted by NCI funded extramural clinical networks in several solid tumor and hematologic cancers.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
